Liraglutide Associated with Less Progression in Prediabetes (FREE)
By Joe Elia
Edited by William E. Chavey, MD, MS
Patients with prediabetes were less likely to have developed type 2 diabetes after 3 years ' treatment with liraglutide than with placebo, according to a Lancet … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 22, 2017 Category: Primary Care Source Type: news
New approach to reduce risk of developing type 2 diabetes trialled in Liverpool
(University of Liverpool) An international clinical trial conducted by the University of Liverpool has shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80 percent in individuals with obesity and prediabetes according to a study published today in The Lancet. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 22, 2017 Category: Global & Universal Source Type: news
Liraglutide Reduces Risk of Heart Events
(MedPage Today) -- Widely-anticipated cardiovascular outcomes trial delivers positive result (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 3, 2017 Category: Cardiology Source Type: news
Trying to Live Normally: ADA's 2017 Focus on Whole Patient Trying to Live Normally: ADA's 2017 Focus on Whole Patient
New American Diabetes Association guidelines also address early type 1 diabetes screening, defining hypoglycemia, new roles for empagliflozin and liraglutide, and vitamin B12 deficiency with metformin use.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Xultophy Injection (Insulin Degludec and Liraglutide) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 2, 2016 Category: Drugs & Pharmacology Source Type: news
Monthly News Roundup - November 2016
Novo Nordisk ’s Xultophy 100/3.6 FDA-Approved for Type 2 Diabetes
This month the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), a once-daily injection of insulin degludec... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2016 Category: Pharmaceuticals Source Type: news
IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes
The first approval for GLP-1 agonist lixisenatide/insulin glargine combo from Sanofi for type 2 diabetes in US will be marketed as Soliqua. Novo Nordisk product Xultophy combines liraglutide and insulin degludec.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 22, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news
Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection)
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Saxenda (Liraglutide [rDNA Origin]) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 14, 2016 Category: Drugs & Pharmacology Source Type: news
Victoza (Liraglutide [rDNA] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 22, 2016 Category: Drugs & Pharmacology Source Type: news
More LEADER: Liraglutide Delays Progression of Renal Events More LEADER: Liraglutide Delays Progression of Renal Events
Nephropathy results from the LEADER trial show that liraglutide reduces renal events by 22% compared with placebo, mainly driven by reduction in new-onset macroalbuminuria.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Victoza (liraglutide)
Title: Victoza (liraglutide)Category: MedicationsCreated: 2/17/2012 12:00:00 AMLast Editorial Review: 9/14/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 14, 2016 Category: Endocrinology Source Type: news
Switching GLP-1 For DPP-4 Improves Net T2D Outcomes
(MedPage Today) -- Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 13, 2016 Category: Cardiology Source Type: news
